Cellectis S.A. · EURONEXT:ALCLS

Cellectis — Investor Presentation (January 2018)

25 slides from Cellectis's investor presentation, January 2018

  1. Slide 1: Gene Edited CAR-T Therapies: The Paradigm in Oncology

    GENE EDITED CAR-T THERAPIES THE PARADIGM IN ONCOLOGY Cellectis, January 2018

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS THIS PRESENTATION CONTAINS “FORWARD-LOOKING” STATEMENTS THAT ARE BASED ON OUR MANAGEMENT’S CURRENT EXPECTATIONS AND ASSUMPTIONS AND ON INFORMATION CURRENTLY AVAILABLE TO MANAGEMENT. FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS

  3. Slide 3: The Cellectis Group

    The Cellectis Group ∼80% ownership § NASDAQ: CLLS § EURONEXT GROWTH: ALCLS § 36M SHARES OUTSTANDING § NASDAQ: CLXT § $297M IN CASH END Q4 2017 § IPO JULY 2017 § $56M IN CASH END Q4 2017 § IMMUNO-ONCOLOGY / CAR T § 7.7M SHARES OUTSTANDING (27M § THERAPEUTIC GENE EDITING TOTAL) § GENE THERAPY § BASED

  4. Slide 4: Leader in Allogeneic CAR-T

    Leader in Allogeneic CAR-T n 2017 market: CAR-T in the spotlight Ø CAR-Ts are here to stay Ø First FDA approved autologous CAR-Ts on the market Ø Allogeneic CAR-Ts concept validated n Allogeneic CAR-Ts: major uncertainties relativized Ø First market challenges for autologous CAR-Ts ✓ ◻ Industrialize

  5. Slide 5: Rich Allogeneic CAR T Pipeline

    Rich Allogeneic CAR T Pipeline Addressing unmet medical need with proven targets Product Manufactu- Program Indication Preclinical IND Filing* Phase I Ph II Ph III development ring ALL (PALL) UCART19** ALL (CALM) AML UCART123 BPDCN B-ALL UCART22 B-NHL UCARTCS1 MULTIPLE MYELOMA n 2 UCART in clinic: U

  6. Slide 6: Life threatening diseases with unmet needs

    Life threatening diseases with unmet needs Allowing for potential fast track development plans Estimated New Cases in Estimated Deaths in 5 Year Survival US Estimate 2017 2017 (2007-2013) AML* 21,000 10,000 26,9% BPDCN Estimated < 1% of all hematologic malignancies** 38%*** ALL* 6,000 1,500 68,2% CL

  7. Slide 7: Allogeneic CAR T – GMP Manufacturing

    Allogeneic CAR T – GMP Manufacturing n GMP manufacturing in place for UCART19, UCART123, UCART22 n Full QC system, cleared for clinical trials 7

  8. Slide 8: Proprietary TALEN Gene Editing

    Proprietary TALEN® Gene Editing Highest yield and precision Ø Industry-leading knockout and knock- in efficiency Ø Precision targeting to 6 base pairs at the cleavage site Ø Low off-target cleavage Ø 18 years of experience in gene editing Ø Strong intellectual property A powerful gene editing techno

  9. Slide 9: A cornerstone: TALEN gene editing

    A cornerstone: TALEN® gene editing Highest yield and precision Ø 90% double knockout of TCR and B2M in T Cells Ø 68% efficiency targeted insertion (CAR) with double knockout (TCR, B2M) Ø 42% double targeted insertion (CAR, NK inhibitor) at TRAC and B2M locus with double knockout (TCR, B2M) 9

  10. Slide 10: The benefits of UCARTs

    The benefits of UCARTs Market access § Ability to manufacture large amounts of product in advance § Easily available in large number of hospitals Cost of treatment § Possibility to lower the price range of CART therapies to other IO standard (~150k$) § No additional cost linked to “segment of one” s

  11. Slide 11: UCART19 Initial Proof Of Concept in ALL

    UCART19* Initial Proof Of Concept in ALL § 1st patient dosed in June 2015 (compassionate) § Phase I trials (US/EU) started in June 2016 Tumor cell § Multiple recruiting centers (EU and US) § 14 patients treated disclosed (7 adults and 7 pediatric)** § Results in line with early autologous CAR-T UCAR

  12. Slide 12: Early Clinical Data UCART19 in Pediatric ALL patients

    Early Clinical Data UCART19* in Pediatric ALL patients (ASH 2017) Lymphodepletion Disease status before Dose level MRD- CR/CRi Adverse Relapse & patient age treatment (CAR-T event follow up Cells/kg) > Grade 3 SERVIER & KCL CFA All patients were ineligible for or 1.1 to 2.3x106 100% (7/7)* CRS 14% (

  13. Slide 13: Early Clinical Data UCART19 in Adult ALL patients

    Early Clinical Data UCART19* in Adult ALL patients (ASH 2017) Lymphodepletion Disease status before Dose level MRD- CR/CRi Adverse Relapse & patient age treatment (CAR-T event follow up Cells/kg) > Grade 3 SERVIER & KCL CFA 1-5 lines of treatment, 4/6 Total 6x106 71% (5/7)* CRS 14% (1/7) 25% (1/4) -

  14. Slide 14: UCART123 in AML and BPDCN: Encouraging Efficacy Data

    UCART123 in AML and BPDCN Encouraging Efficacy Data § Significant improvement compared to Cytarabine standard-of-care (Ara-C) Peripheral Blood Evaluation Overall Survival Ara-C UCART123 2.5M TCRα/β KO UCART123 1M UCART123 2.5M Ara-C TCRα/β KO UCART123 1M Treatments Started Day 24 § Encouraging resul

  15. Slide 15: UCART123 First Wholly-Controlled CAR-T In The Clinic

    UCART123 in AML and BPDCN First Wholly-Controlled CAR-T In The Clinic § AML Ph 1 dose escalation trial at Weill Cornell § First patient dosed in June 2017 § Expansion to others centers in 2018 Dose Escalation Phase (R/R AML) Expansion Phase DL3 1.25x106/kg N=3 RR AML DL2 N=18-37 1.25x105/kg N=3 3 Pa

  16. Slide 16: UCART123 Development plan

    UCART123 in AML and BPDCN Development plan Preclinical Proof of Concept UCART123 Q4 2016 § In vitro and in vivo development finalized ✓ Manufacturing UCART123 § High yield, high potency cGMP batches Q4 2016 ✓ IND for both indications Q1 2017 § AML Cornell-Weill ✓ § BPDCN MD Anderson Phase 1 Q2-Q3 20

  17. Slide 17: UCART22 Targeting ALL, NHL and other B-Cell Malignancies

    UCART22 Targeting ALL, NHL and other B-Cell Malignancies Unmet Medical Need Rationale § Relapse after CD19 CAR-T treatment § Both CD22 and CD19 are expressed § Numerous ALL relapsing patients are on various B-cells CD19- but CD22+ § CD22 expression frequently maintained in CD19-negative blasts1 Targ

  18. Slide 18: UCART22 Strong anti-tumoral activity

    UCART22 Strong anti-tumoral activity § UCART22 is highly efficient at eradicating tumors in vivo § UCART22 cells result in increased mice survival CD22+ cell line show no tumor progression Survival curves 1,E+10 G1 Vehicle 100 1,E+09 G2 DKO/NT 10x10E6 cells Biolum signal (ph/s/sr) G5 3x10E6 UCART22

  19. Slide 19: UCART22 Development Plan

    UCART22 Development Plan Proof of concept Q4 2016 § In vitro cytotoxic activity demonstrated in CD22+ cell lines ✓ § Generation of anti-CD22 proprietary monoclonal antibodies (selection ongoing) In vivo studies § Preclinical studies in collaboration with MD Anderson Cancer Center Q3 2017 ✓ Manufactu

  20. Slide 20: UCARTCS1 Targeting Multiple Myeloma

    UCARTCS1 Targeting Multiple Myeloma Unmet Medical Need Target Antigen § > 30,000 patients / year in the US § Well proven target with § High relapse rate, median OS of 9 Elotuzumab (BMS/Abbvie) as PoC months § CS1 (SLAMF7) is highly expressed on MM cancer cells UCARTCS1 Attributes § TCR gene disrupti

  21. Slide 21: UCARTCS1 Anti-tumor activity with durable efficacy

    UCARTCS1 Anti-tumor activity with durable efficacy § UCART CS1 exhibits durable in vivo efficacy in high-risk MM in PDX-MM models 21

  22. Slide 22: UCARTCS1 Anti-tumor activity: re-dosing can increase efficacy

    UCARTCS1 Anti-tumor activity: re-dosing can increase efficacy 100 Percent survival 75 Vehicle UCARTCS1 3E6 50 UCARTCS1 3E6 redosing UCARTCS1 10E6 UCARTCS1 10E6 redosing 25 0 0 10 20 30 40 50 60 70 80 90 100 110 Times (days) Day 0 Day 25 Treatment 1 Treatment 2 22

  23. Slide 23: UCARTCS1 Development Plan

    UCARTCS1 Development Plan Proof of Concept § Increased cytotoxic activity compared to non-edited T Cells Q4 2016 ✓ In vivo studies Ongoing § Preclinical studies ongoing in collaboration with MD Anderson Cancer Center ✓ (Dr. Jing Yang and Dr. Sattva Neelapu) Manufacturing Expected in 2018 § Developme

  24. Slide 24: 18 months expected Milestone Timeline

    18 months expected Milestone Timeline 2018 2019 Q1 Q2 Q3 Q4 Q1 Q2 UCART19 Ph1 Ongoing Interim data update UCART123 1st Dose (3 pts) 2nd Dose (3 pts) Interim data update UCART22 Manufacturing IND Filing Interim data update UCART CS1 Manufacturing IND Filing § UCART19 in ALL patients – Ph1 clinical tr

  25. Slide 25: Thank You

    THANK YOU Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris – France Cellectis, Inc. 430 East 29th Street 10016 New York, NY – USA investors@cellectis.com

Cellectis — Investor Presentation (January 2018) on 6ix